Company research
ALUMIS INC.
CIK 1847367Updated Sep 26, 2026
SecurityALMS · NASDAQ · equity
Name history
FL2021-001, Inc. · through Mar 19, 2021
ALMS price & chart
Loading TradingView…
NASDAQ:ALMS on TradingView ↗About the company
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases, such as Parkinson’s disease. In addition, the pipeline includes several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
In the news
Alumis to Present at the Leerink Partners Global Healthcare Conference ↗
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders News provided by Halper Sadeh LLP Apr 01, 2025, 10:51 ET Share this article Share to X Share this article Share to X NEW YORK , April 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights ↗
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, FNA, ALMS, HEES on Behalf of Shareholders News provided by Halper Sadeh LLP Feb 10, 2025, 18:15 ET Share this article Share to X Share this article Share to X NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights ↗
Seeking Alpha
10 small-cap U.S. healthcare stocks with the weakest momentum grades ↗
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow ↗
Recent filings
4 filing
Other Events
Items 8.01, 9.01
SCHEDULE 13D filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
4 filing
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 411,940,000Source | 340,992,000Source | 89,612,000Source |
| Property, Plant and Equipment, NetUSD | 18,190,000Source | 20,968,000Source | 22,441,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 89,670,000Source | 169,526,000Source | 45,996,000Source |
| Assets, CurrentUSD | 318,232,000Source | 306,188,000Source | 53,357,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,740,000Source | 4,501,000Source | 1,631,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,971,000Source | 12,723,000Source | 12,783,000Source |
| Other Assets, NoncurrentUSD | 6,287,000Source | 7,000Source | 7,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 110,643,000Source | 80,888,000Source | 53,502,000Source |
| Stockholders’ equity: | |||
| Additional Paid in CapitalUSD | 1,202,975,000Source | 918,610,000Source | 25,055,000Source |
| Retained Earnings (Accumulated Deficit)USD | -901,876,000Source | -658,551,000Source | -364,318,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 188,000Source | 40,000Source | 2,000Source |
| Stockholders' Equity Attributable to ParentUSD | 301,297,000Source | 260,104,000Source | -339,260,000Source |
| Liabilities and EquityUSD | 411,940,000Source | 340,992,000Source | 89,612,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 73,318,000Source | 50,910,000Source | 20,871,000Source |
| Operating Lease, Liability, CurrentUSD | 4,670,000Source | 1,557,000Source | 1,720,000Source |
| Accounts Payable, CurrentUSD | 10,106,000Source | 9,624,000Source | 1,118,000Source |
| Operating Lease, Liability, NoncurrentUSD | 32,244,000Source | 29,165,000Source | 30,860,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,140,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 207,000Source | — | — |
| Additional Financial Items | |||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 308,500,000Source | 288,300,000Source | — |
| Deferred Tax Liabilities, NetUSD | 2,140,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -243,325,000Source | -294,233,000Source | -154,993,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 3,496,000Source | 3,152,000Source | 1,284,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 43,524,000Source | 19,457,000Source | 8,625,000Source |
| Deferred Income Tax Expense (Benefit)USD | -8,561,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -369,523,000Source | -255,078,000Source | -129,975,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 287,877,000Source | -113,790,000Source | 60,472,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 653,000Source | 1,732,000Source | 4,499,000Source |
| Cash flows from financing activities: | |||
| Payments for Repurchase of Common StockUSD | 17,000Source | 6,000Source | 64,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,067,000Source | 492,367,000Source | 89,682,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 91,053,000Source | 170,632,000Source | 47,133,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 43,524,000Source | 19,457,000Source | 8,625,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 308,500,000Source | 288,300,000Source | — |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 0Source | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | -5,406,000Source | -119,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -5,000Source | -266,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | -645,000Source |
| General and Administrative ExpenseUSD | 91,856,000Source | 35,200,000Source | 20,498,000Source |
| Income Tax Expense (Benefit)USD | -8,561,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -243,325,000Source | -294,233,000Source | -154,993,000Source |
| Nonoperating Income (Expense)USD | 201,918,000Source | 6,521,000Source | 3,181,000Source |
| Operating ExpensesUSD | 477,854,000Source | 300,754,000Source | 158,174,000Source |
| Other Nonoperating Income (Expense)USD | -169,000Source | -93,000Source | -68,000Source |
| Proceeds from Stock Options ExercisedUSD | 489,000Source | 596,000Source | 453,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 24,050,000Source | — | — |
| Operating Income (Loss)USD | -453,804,000Source | -300,754,000Source | -158,174,000Source |
| Other Nonoperating Income (Expense)USD | -169,000Source | -93,000Source | -68,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -251,886,000Source | — | — |
| Income Tax Expense (Benefit)USD | -8,561,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -243,325,000Source | -294,233,000Source | -154,993,000Source |
| Earnings Per Share, BasicUSD per share | -2.86Source | -10.38Source | -72.08Source |
| Earnings Per Share, DilutedUSD per share | -2.86Source | -10.38Source | -72.08Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 85,029,624Source | 28,341,866Source | 2,150,186Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 85,029,624Source | 28,341,866Source | 2,150,186Source |
| Additional Financial Items | |||
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,500,000Source | 3,200,000Source | 1,300,000Source |
| General and Administrative ExpenseUSD | 91,856,000Source | 35,200,000Source | 20,498,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -251,886,000Source | — | — |
| Nonoperating Income (Expense)USD | 201,918,000Source | 6,521,000Source | 3,181,000Source |
| Operating ExpensesUSD | 477,854,000Source | 300,754,000Source | 158,174,000Source |
| Research and Development ExpenseUSD | 385,998,000Source | 265,554,000Source | 137,676,000Source |
Offerings
Registration 333-286660
Registration 333-286178
Filing attachments
tm2624540d1_ex99-1.htm · 8-K · 2026-09-01
EX-99.1 2 tm2624540d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) - LUMUS trial did not meet its primary and secondary endpoints in the overall trial population - - Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE - - Pharmacodynamic data substantiate envudeucitinib’s potential i…
Read attachment ↗tm2624540d1_ex99-2.htm · 8-K · 2026-09-01
EX-99.2 3 tm2624540d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Transform Therapies. Reimagine Lives. LUMUS Phase 2b Topline Results September 1, 2026 Forward - Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward - looking statements are based upon current plans, estimates and expectations of management of Alumis Inc. (“ Alum…
Read attachment ↗alms-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 alms-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements - ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO - - Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 - - Potentially pivotal Phase 2b LUMUS topline data for envudeuc…
Read attachment ↗tm2622655d1_ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 tm2622655d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies - ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment - - Favorable long-term safety and tolerability profile remained consistent with previously reported data - - On track to submit a N…
Read attachment ↗tm2619143d1_ex99-1.htm · 8-K · 2026-06-29
EX-99.1 2 tm2619143d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 Transforming Immune-Mediated Disease Treatment with Precision Engineered TYK2 Inhibitors Corporate Deck: June 2026 ──────────────────────────────────── 2 Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current…
Read attachment ↗alms-20260514xex99d1.htm · 8-K · 2026-05-14
EX-99.1 2 alms-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements - Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms - - Data showed robust PASI responses by Week 16, with significant continued impro…
Read attachment ↗